Schizophrenia

Risperdal Consta significantly reduces need for institutional psychiatric care

Published in Health and Medicine Week, March 8th, 2004

People with schizophrenia treated with Risperdal Consta (risperidone long-acting injection) are significantly less likely to be admitted to hospital than before they were treated with this new therapy, according to a Swedish study presented at the Twelfth Biennial Winter Workshop on Schizophrenia in Davos, Switzerland.

Furthermore, patients who were hospitalized during their treatment with Risperdal Consta had significantly shorter hospital stays than before treatment with the new therapy. The reduction in both the number and duration of hospitalizations associated with the use of Risperdal Consta resulted in substantial cost savings for the Swedish health care...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2004-03-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry